- Policy
- What is the pledge of the presidential candidates?
- by Lee, Jeong-Hwan Feb 18, 2022 05:54am
- With the 20th presidential election day just 20 days away, candidates from each party completed submitting their teenage pledges with the registration of candidates for the National Selection Commission on the 13th. The main keyword for the health care pledge of Democratic Party of Korea Lee Jae-myung, the power of the people Yoon Seok-yeol,
- Company
- The development of next lung cancer txs is in full swing
- by Feb 17, 2022 05:53am
- Starting with EGFR, treatments have been released. The first dual inhibitor was also released. Non-small cell lung cancer treatment is facing a new turning point with the emergence of various targeted anticancer drugs. Precise treatment began by pioneering areas where there were no treatments, such as KRAS, MET, and EGFR Exon 20. ◆ New
- Opinion
- [Reporter’s View] Why set deadlines in pricing negotiations
- by Eo, Yun-Ho Feb 17, 2022 05:53am
- A deadline is a pre-determined set amount of period. If this period is extended frequently, what meaning would setting a ‘deadline’ have? This question arises with the uprise of deadline extensions being made in the drug pricing negotiations between the National Health Insurance Service and pharmaceutical companies for reimbursement lis
- Company
- Seqirus “to supply next-gen influenza vaccine” in Korea
- by Feb 17, 2022 05:53am
- A new competitor has entered the influenza vaccine market. Seqirus, a subsidiary of the Australia-based biotech firm CSL, will be entering the Korean market in earnest in the COVID-19 pandemic. Seqirus Korea held an online press conference to celebrate the official launch of its Korean subsidiary on the 16th. At the conference, Seqirus th
- Policy
- Rybrevant has been approved in Korea
- by Lee, Tak-Sun Feb 17, 2022 05:52am
- Janssen's Rybrevant, which is conducting a combined clinical trial with Leclaza, a new non-small cell lung cancer treatment drug developed by Yuhan Corporation, has been approved in Korea. The MFDS approved Janssen's Rybrevant on the 15th. This drug is used for "the treatment of patients with local progressive and metastatic non-small cell
- Policy
- Revised the method of Rx notes for health functional foods
- by Lee, Jeong-Hwan Feb 17, 2022 05:52am
- Regarding the regulation of "Note Prescription of Health Functional Foods," the MFDS expressed its position to push for legislation after watching the operation of the prohibited regulation that the health functional food industry voluntarily announced. The government plans to steadily monitor the operation of fair competition rules, draw up
- Company
- Roche's Polivy can be prescribed at Big 5 hospitals
- by Eo, Yun-Ho Feb 16, 2022 05:51am
- The new lymphoma drug Polivy can be prescribed at the Big 5 General Hospital. According to related industries, Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, Seoul National University Hospital, and Antibody-drug conjugate (ADC) Polivy, which combines with existing BR therapy (Bendamustine & Rituximab) f
- Policy
- Lee to pledge ‘incentives for homegrown new drugs'
- by Lee, Jeong-Hwan Feb 16, 2022 05:51am
- Presidential candidate Jae-Myung Lee of the Democratic Party of Korea is positively reviewing reinforcing incentives for new drugs that were developed by Korean pharmaceutical companies or conducted trials in Korea, establishing a megafund for the pharmaceutical industry, and introducing a pre-approval system for prescriptions of ultra-high
- Company
- GC Pharma & SK Bioscience are competing
- by Ji Yong Jun Feb 16, 2022 05:51am
- GC Pharma's Barycela challenges the international procurement market. Competition among domestic companies in the international procurement market for chickenpox virus vaccines is likely to begin in earnest. SK Bioscience seems to be challenging first while undergoing the World Health Organization (WHO) certification process for overseas sale
- Company
- Amgen’s Lumakras approved in Korea… first-ever approved
- by Feb 16, 2022 05:51am
- Amgen Korea announced on the 15th that the Ministry of Food and Drug Safety approved its ‘Lumakras (sotorasib)’ for the treatment of KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer on the 15th. Lumakras is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic no
